Below is a summary of the key data being presented at the 2013 American Urological Association annual meeting.
POSTER #985: Value of Cell Cycle Progression (CCP) Score to Predict Biochemical Recurrence (BCR) and Definitive Post-Surgical Pathology
Poster Presentation, Monday, May 6, 2013
Results from this prospectively-designed clinical study show that in patients who underwent radical prostatectomy, PROLARIS (CCP) score correlated significantly with organ confined, local invasive and systemic tumor growth, and these correlations remained after adjusting for Gleason score, PSA level and clinical stage. The PROLARIS score significantly represents real clinically and biologically relevant tumor features qualifying it as a promising biomarker for active surveillance in the post-surgical decision making processes as well as pre-surgical decision making processes as demonstrated in earlier clinical studies.Key findings from this study demonstrate that the PROLARIS test was:
- A highly significant predictor of biochemical recurrence;
- Identified as a significant factor in predicting pathologic stage T3 cancer; and
- The best predictor for biochemical recurrence in low risk patients, whereas Gleason score was not significant.
- 57 percent of study subjects from the Durham VA Medical Center were African Americans;
- The PROLARIS score was a significant prognostic variable (the hazard ratio for biochemical recurrence was 2.55);
- The PROLARIS test provides prognostic information that is not provided by standard clinical parameters; and
- The PROLARIS score was significantly associated with prostate cancer specific mortality.